| US 7,541,350 B2 | ||
| Formulation containing anti-inflammatory androstane derivative | ||
| Keith Biggadike, Stevenage (United Kingdom); Amyn Pyarali Sayani, Mississauga (Canada); Ian Richard Buxton, Mississauga (Canada); and Kenton Lewis Reed, Mississauga (Canada) | ||
| Assigned to Glaxo Group Limited, Greenford, Middlesex (United Kingdom) | ||
| Filed on Aug. 13, 2004, as Appl. No. 10/918,779. | ||
| Application 10/918779 is a continuation of application No. 10/067020, filed on Feb. 04, 2003, granted, now 6,858,596. | ||
| Application 10/067020 is a continuation in part of application No. 09/958050, granted, now 7,101,866, previously published as PCT/GB01/03495, filed on Aug. 03, 2001. | ||
| Claims priority of application No. 0019172.6 (GB), filed on Aug. 05, 2000. | ||
| Prior Publication US 2005/0020549 A1, Jan. 27, 2005 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/58 (2006.01); C07J 17/00 (2006.01) | ||
| U.S. Cl. 514—172 [540/114] | 7 Claims |
1. A pharmaceutical formulation comprising an aqueous suspension of particulate unsolvated polymorph Form 1 of compound of
formula (I)
 one or more suspending agents,
one or more preservatives,
one or more wetting agents, and
one or more isotonicity adjusting agents.
|